| Comprehensive Home Care | |
| 7105 Allen Road Upper Level, Allen Park, Michigan 48101 | |
| (313) 791-7094 | |
| Name | Comprehensive Home Care |
|---|---|
| Location | 7105 Allen Road Upper Level, Allen Park, Michigan |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 239163 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 48034, 48060, 48066, 48088, 48091, 48093, 48120, 48134, 48135, 48138, 48141, 48146, 48150, 48152, 48170, 48173, 48174, 48176, 48180, 48184, 48192, 48195, 48197, 48203, 48206, 48207, 48209, 48210, 48212, 48213, 48215, 48217, 48218, 48219, 48221, 48223, 48224, 48227, 48228, 48234, 48238, 48239, 48307, 48310, 48313, 48331 |
| NPI Number | 1770723835 |
| Organization Name | COMPREHENSIVE HOMECARE, LLC |
| Address | 7105 Allen Rd, Allen Park, MI 48101 |
| Phone Number | 313-791-7094 |
News Archive
Researchers at the University of Toronto have uncovered new insights on the genetic causes of Amyotrophic Lateral Sclerosis (ALS), which is also known as Lou Gehrig's disease. These findings could uncover a new way to detect a genetic predisposition to ALS before the disease strikes.
Scientists have known for some time that these individuals carry a genetic mutation (known as CCR5-Ä32) that prevents the virus from entering the cells of the immune system but have been unable to account for the high levels of the gene in Scandinavia and relatively low levels in areas bordering the Mediterranean.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.
A new study conducted at the Swinburne's Centre for Mental Health suggests that the reward center of the brain works differently across the day, with it's peak being in the morning and evening.
› Verified 4 days ago
| Quality Rating: |
News Archive
Researchers at the University of Toronto have uncovered new insights on the genetic causes of Amyotrophic Lateral Sclerosis (ALS), which is also known as Lou Gehrig's disease. These findings could uncover a new way to detect a genetic predisposition to ALS before the disease strikes.
Scientists have known for some time that these individuals carry a genetic mutation (known as CCR5-Ä32) that prevents the virus from entering the cells of the immune system but have been unable to account for the high levels of the gene in Scandinavia and relatively low levels in areas bordering the Mediterranean.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.
A new study conducted at the Swinburne's Centre for Mental Health suggests that the reward center of the brain works differently across the day, with it's peak being in the morning and evening.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 96.1 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 94.3 | 98.6 |
| How often the home health team checked patients’ risk of falling | 97.4 | 99.6 |
| How often the home health team checked patients for depression | 100 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 67.7 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 55.9 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 93.3 | 96.4 |
News Archive
Researchers at the University of Toronto have uncovered new insights on the genetic causes of Amyotrophic Lateral Sclerosis (ALS), which is also known as Lou Gehrig's disease. These findings could uncover a new way to detect a genetic predisposition to ALS before the disease strikes.
Scientists have known for some time that these individuals carry a genetic mutation (known as CCR5-Ä32) that prevents the virus from entering the cells of the immune system but have been unable to account for the high levels of the gene in Scandinavia and relatively low levels in areas bordering the Mediterranean.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.
A new study conducted at the Swinburne's Centre for Mental Health suggests that the reward center of the brain works differently across the day, with it's peak being in the morning and evening.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 60.9 | 79.6 |
| How often patients got better at getting in and out of bed | 79.1 | 81.1 |
| How often patients got better at bathing | 76.7 | 82.3 |
| How often patients’ breathing improved | 85.9 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 73.7 | 75 |
| How often home health patients had to be admitted to the hospital | 15.5 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 13.7 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 81.5 | 94 |
News Archive
Researchers at the University of Toronto have uncovered new insights on the genetic causes of Amyotrophic Lateral Sclerosis (ALS), which is also known as Lou Gehrig's disease. These findings could uncover a new way to detect a genetic predisposition to ALS before the disease strikes.
Scientists have known for some time that these individuals carry a genetic mutation (known as CCR5-Ä32) that prevents the virus from entering the cells of the immune system but have been unable to account for the high levels of the gene in Scandinavia and relatively low levels in areas bordering the Mediterranean.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.
A new study conducted at the Swinburne's Centre for Mental Health suggests that the reward center of the brain works differently across the day, with it's peak being in the morning and evening.
› Verified 4 days ago
News Archive
Researchers at the University of Toronto have uncovered new insights on the genetic causes of Amyotrophic Lateral Sclerosis (ALS), which is also known as Lou Gehrig's disease. These findings could uncover a new way to detect a genetic predisposition to ALS before the disease strikes.
Scientists have known for some time that these individuals carry a genetic mutation (known as CCR5-Ä32) that prevents the virus from entering the cells of the immune system but have been unable to account for the high levels of the gene in Scandinavia and relatively low levels in areas bordering the Mediterranean.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.
A new study conducted at the Swinburne's Centre for Mental Health suggests that the reward center of the brain works differently across the day, with it's peak being in the morning and evening.
› Verified 4 days ago
Rn Home Health Care Location: 4611 Allen Rd, Allen Park, Michigan 48101 Ratings: NA Phone: (313) 551-5814 | |
Guidance Home Health Services Location: 7312 Park Ave, Allen Park, Michigan 48101 Ratings: Phone: (313) 382-3844 | |
Comprehensive Home Care Location: 7105 Allen Road Upper Level, Allen Park, Michigan 48101 Ratings: Phone: (313) 791-7094 |